Hide Message

Updating the Resource Centre Digital Platform

The Business & Human Rights Resource Centre is at a critical point in its development. Our digital platform is home to a wealth of information on business and human rights, but hasn’t had a visual refresh for a number of years.

We will soon be updating the site to improve its usability and better serve the thousands of people that use our site to support their work.

Please take an advance peek at our new look, and let us know what you think!

Thank you,
Alex Guy, Digital Officer

Find Out More Hide Message

You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:

Media Kit 2014 Index

Author: Access to Medicines Index, Published on: 18 November 2014


Press release in English, German, French, Spanish, Dutch, Japanese

2014 Access to Medicine Index Key Findings    

Overall ranking analysis 2014 Access to Medicine Index    

2014 Access to Medicine Index - Executive Summary
Executive Summary 2014 Access to Medicine Index - PDF

Full Report 2014 Access to Medicine Index

Companies in the index (in order from highest to lowest ranked): GlaxoSmithKline; Novo Nordisk; Johnson & Johnson; Novartis AG; Gilead Sciences Inc; Merck KGaA;
Merck & Co; Sanofi; AbbVie; Bayer AG; Eisai Co. Ltd; Roche Holding AG; Bristol-Myers Squibb Co; Boehringer Ingelheim GmbH; AstraZeneca plc; Pfizer Inc.; Eli Lilly & Co; Astellas Pharma Inc.; Daiichi Sankyo Co. Ltd.; Takeda Pharmaceutical Co.

Read the full post here

Related companies: AbbVie AstraZeneca Bayer Boehringer Ingelheim Bristol-Myers Squibb Daiichi Sankyo Eisai Eli Lilly Gilead Sciences GlaxoSmithKline Johnson & Johnson Merck Novartis Novo Nordisk (part of Novo Group) Pfizer Roche Sanofi Takeda Pharmaceutical